Risk for Second Primary Cancer May Be No Higher With CAR T-Cell Versus Standard of Care
By Elana Gotkine HealthDay Reporter
THURSDAY, Sept. 12, 2024 -- The overall second primary malignancy (SPM) point estimate was 5.8 percent for patients receiving chimeric antigen receptor (CAR) T-cell therapy, according to a study published online Sept. 11 in Clinical Cancer Research.
Tobias Tix, from LMU Klinikum in Munich, and colleagues conducted a systematic review to delineate the frequency and subtypes of SPMs following CAR T-cell therapy in lymphoma and myeloma. A total of 326 SPMs were identified across 5,517 patients from 18 clinical trials and seven real-world studies.
The researchers found that the overall SPM point estimate was 5.8 percent with a median follow-up of 21.7 months. There were associations for SPM estimates with treatment setting (clinical trials > real-world settings), follow-up duration, and number of previous treatment lines. In a meta-regression model, these associations were confirmed as independent study-level risk factors for SPM. The risk for SPM was similar with either treatment strategy in a subgroup meta-analysis of four trials that randomly assigned patients to CAR T-cell therapy versus standard of care. In an analysis of SPM subtypes, the most common were hematologic malignancies, followed by solid tumors and nonmelanoma skin cancers (37, 27, and 16 percent, respectively). A small minority of events were T-cell malignancies (1.5 percent).
"By understanding the factors contributing to SPM development and implementing effective monitoring strategies, health care providers can optimize patient outcomes and ensure the long-term safety of CAR T-cell therapies," the authors write.
Several authors disclosed ties to the pharmaceutical industry.
Abstract/Full Text (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2025 HealthDay. All rights reserved.
Posted September 2024
Read this next
Surgeons Have Higher Mortality Rates Than Other Physicians
TUESDAY, Aug. 5, 2025 -- Surgeons have higher mortality rates than nonsurgeon physicians and individuals in other fields, according to a research letter published online July 30...
Study Offers Comprehensive Evaluation of Survival Parameters for Pediatric CNS Tumors
MONDAY, Aug. 4, 2025 -- The survival probabilities of pediatric central nervous system (CNS) tumors in Europe have been explored in a study published in the August issue of The...
Cannabis Use Disorder Linked to Increased Risk for Oral Cancer
FRIDAY, Aug. 1, 2025 -- Cannabis use disorder (CUD) is associated with an increased risk for oral cancer, according to a study published in the September issue of Preventive...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.